Biodegradable Long Acting Injectables and Implants

An Industry View

Farshad Ramazani

$415.95 $332.78

Hardback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Springer International Publishing AG
30 March 2025

Medical research; Pre-clinical medicine: basic sciences; Pharmacology; Chemistry; Pharmaceutical technology

Long acting injectables and implants (LAI) are known to improve patient adherence and treatment outcomes. They reduce costs for the healthcare system and ensure sustainable sales for pharmaceutical companies. LAI are usually administered intramuscularly (IM) or subcutaneously (SC). In this way, the drug is released from its depot in a controlled manner over a longer period of time (e.g., a few days to a year). There is a trend toward increasing interest in the development of long-acting drugs for local administration versus systemic administration of depot products (i.e., IM or SC injection). This is leading to finding new ways of administration of the depot formulation, intra-ocular, intra-articular, pri-tendon etc. Therefore, it is expected that more drugs based on LAI formulations will enter the clinical phase in the future. Due to many benefits in adherence, efficacy, and safety of the treatment up until now around 50 brand name medicines using different biodegradable long-acting technology have received FDA approval. Manufacturing of LAI involves many steps with their unique challenges, which is why pharmaceutical companies consider them to be complex formulations to develop. Most of the published papers and books in this field are written by scientists who never worked in industry and whose knowledge on the topic is limited to small scale formulation screening. Therefore, this book aims to address the challenges of the development of biodegradable LAI from an industrial perspective.

Edited by: Farshad Ramazani
Imprint: Springer International Publishing AG
Country of Publication: Switzerland
Edition: 2025 ed.
Dimensions: Height: 235mm, Width: 155mm,
ISBN: 9783031723018
ISBN 10: 3031723015
Pages: 256
Publication Date: 30 March 2025
Audience: Professional and scholarly , College/higher education , Undergraduate , Further / Higher Education
Format: Hardback
Publisher's Status: Active

Preface.- Drug design for the development of long acting injectables.- Biodegradable polymers for development of LAI.- A roadmap for production of drug loaded poly (lactic-co-glycolic acid) (PLGA) microparticles: challenges and opportunities.- Biodegradable in situ forming and preformed implants.- Suspension-Based Long Acting Injectables.- Oil based solutions.- Clinical applications of LAI: systemic and local drug delivery.- Local Tolerability of Long-acting Injectables.- Envisaging the future.

Dr. Farshad Ramazani is a Senior Expert Science and Technology at Novartis Pharma AG in Basel, Switzerland, specializing in parenteral drug development. He has been instrumental in developing several patient-centric long-acting injectable formulations, now in various clinical trial phases. Dr. Ramazani regularly publishes research and review articles in leading pharmaceutical journals and is a co-inventor on three patents on long acting injectables. He received the TRD Culture Award in 2021 and 2023, and the Innovation Award of the Year in 2016 at Novartis. In 2010, he was among the top four candidates nationally to receive a PhD scholarship from the Iranian Health Ministry. He completed his PhD in 2015 at Utrecht University in the Netherlands, focusing on polymeric micro and nanoparticles for local and targeted drug delivery.